Search results
relief (via mailed checks, without the need for Class Members to file claims); (v) the fact that Balwani claims to lack meaningful resources to satisfy a judgment in this case, and there are limited Theranos assets for distribution to Theranos’s creditors; (vi) the fact that
Case 2:16-cv-02138-DGC Document 157 Filed 09/29/17 Page 5 of 11 a study on a blood test for the Zika virus using data that was collected from human test subjects without any IRB approval[,]” 16 and 5) that “[d]efendants’ hidden strategy was also
Case 2:16-cv-02138-DGC Document 182 Filed 04/10/18 Page 6 of 62 Plaintiffs timely filed a second amended consolidated class action complaint (“SAC)” in which they assert fourteen causes of action.
Case 2:16-cv-02138-DGC Document 139 Filed 06/13/17 Page 2 of 60 Plaintiffs allege that defendants knew that the Theranos blood tests “were unreliable, not ready-for-market, and failed to meet even basic industry standards,” 11 but that in 2012,
Ramirez v. Baxter Credit Union, Cas No. 3:16-cv-03765 - $825); United States District Court, Middle District of Louisiana (Lane v. Campus Federal Credit Union, Case No. 3:16-cv-00037 - $825); United States District Court for the Western District of Wisconsin (Behrens v. Landmark Credit Union, Case No. 17-cv-
The lawsuit, In re Arizona Theranos, Inc., Litigation, Case No. 2:16-cv-2138, received Final Approval in the U.S. District Court for the District of Arizona on February 6, 2024. The Class Members have reached settlements with Defendants Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Co. (together called “Walgreens”), Defendant ...
California, No. 4:16-cv-03454 and the District of Arizona, No. 2:16-cv-03599, respectively. Each of these matters alleged various tort and consumer protection claims against the Defendants. 3. Once filed, these cases were coordinated into the current litigation. As part of that
